DS-7113b extended-release tablet phase III study

Phase 3

• Conditions: Moderate to severe cancer pain

• Registration Number: JPRN-jRCT2080222615
• Lead Sponsor: DAIICHISANKYO Co.,Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1) Patients receiving non-opioid analgesics for cancer pain, who have not been receiving opioid analgesics
2) Patients whose VAS is  35 mm and judged necessary to be treated with strong opioid analgesics
3) Patients with an ECOG Performance Status (PS) is 3, etc.

Exclusion Criteria

Patients with symptom(s)/finding(s) falling under the contraindications or relative contraindications stated in the package insert for oral oxycodone hydrochloride and morphine hydrochloride, etc.

Study & Design

• Study Type: Interventional
• Study Design: Not specified